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Abstract 
The Type I interferon receptor (IFN-0~R) interacts with all IFN-~s, 1FN-~ and IFN-oL and seems to be a multisubunit receptor. To investigate 
the role of a cloned receptor subunit (IFN-aRI), we have examined the intrinsic ligand binding properties of the bovine and human IFN-~RI 
polypeptides xpressed in Xenopus laevis oocytes. Albeit with different efficiencies, Xenopus oocytes expressing either the human or bovine IFN-~R1 
polypeptide exhibit significant binding and formation of crosslinked complexes with human IFN-~A and IFN-~B. Thus, the IFN-c~R 1polypeptide 
most likely plays a direct role in ligand binding. 
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I. Introduction 
Human Type I interferons (IFN), including multiple 
nonallelic IFN-~s, 1 IFN-fl and 1 IFN-~o, are structur- 
ally similar but they differ in their ability to elicit biolog- 
ical responses in various human cells [1,2-6]. Bovine cells 
respond almost equally to all human IFN-~s, but not to 
HuIFN-f l  [7-9]. 
Type I IFNs bind to a common receptor which is 
composed of several subunits ([10-13]; denoted Type I 
receptor, IFN-~//~ receptor, or IFN-~ receptor). Two 
distinct cDNAs encoding putative human IFN-~ recep- 
tors or receptor subunits have been cloned thus far. A 
cDNA for a human IFN-0~R, here designated IFN- 
c~R 1 **, conferred on transfected mouse cells responsive- 
ness to human IFN-~B, but not to other Type I IFNs 
[14]. However, this HuIFN-~R1 polypeptide is not a 
specific receptor for HuIFN-~B, since antibodies raised 
against he Hu IFN-~R 1 protein neutralize the activities 
of diverse human type I IFNs on human cells [15,16]. 
*Corresponding author. Fax: (1) (908) 235-5223. 
Abbreviations: IFN-~, interferon alpha; IFN-~R, Type I IFN-~ recep- 
tor; IFN-~RI, cloned subunit of the IFN-~R, designated asbovine 
(Bo-) or human (Hu-). 
**The cloned IFN-~R is denoted as IFN-~R1 because of current evi- 
dence that other IFN-~R subunits exist (see text). For IFN-~R sub- 
units, we suggest Arabic numerals, rather than Greek letters ince: (i) 
the interferon receptors already include aGreek letter to denote the a 
or y interferon receptor, and a second Greek letter denoting the various 
subunits of the receptor might be confusing; and (ii) the genetic nomen- 
clature rules do not permit Greek letters, so it will simplify the corre- 
spondence between protein nomenclature and gene nomenclature if 
Greek letters are minimized in the protein omenclature. 
Recently, a second cDNA for a human IFN-~R, here 
referred to as IFN-~R2, has been cloned and initially 
characterized [17]. This cDNA encodes both membrane- 
bound and soluble forms of an IFN receptor which has 
the intrinsic ability to bind several IFN-0cs and IFN-fl. 
As with antibodies to IFN-~R1, antibodies to IFN-~R2 
block the binding of a variety of Type I IFNs to human 
cells [17]. A multi-subunit structure for the IFN-~R is 
also indicated by the results of previous affinity 
crosslinking experiments, which show multiple bands 
representing complexes of cell surface proteins with 
HulFN-~s, and by the characterization f several mono- 
clonal antibodies that appear to recognize cell surface 
polypeptides involved in Type I IFN-0~ binding [18-21]. 
The total number of receptor chains is not yet known, 
but a human chromosome 21-derived YAC, encoding 
HulFN-~R 1 and other polypeptides, is capable of con- 
ferring on hamster CHO cells responsiveness to a variety 
of human Type I IFNs [22]. 
Current results are ambiguous as to whether the 
human IFN-0~R1 protein is directly involved in ligand 
binding. In addition to the original functional character- 
ization of the protein expressed in murine cells ([14]; see 
above), monkey COS-1 cells expressing large amounts of 
HulFN-~R1 do not show enhanced binding of human 
IFN-~A or -0~B ([23]; unpublished ata). These and other 
results have led some investigators to suggest hat the 
IFN-~R1 is primarily involved in signal transduction 
rather than ligand binding [17,24,25]. 
In contrast o the experiments with the HulFN-~R1 
cDNA, monkey COS cells transfected with cDNA en- 
coding the bovine homologue (BolFN-~R1) [23,26] dis- 
play large numbers of high affinity binding sites for 
Hu lFN-~A and -~B [23]. Thus, the BolFN-~R1 pol- 
ypeptide appears sufficient for high-affinity binding of 
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human IFN-~A and -~B [23]. Similarly, the BolFN-~RI 
cDNA confers on human cells an enhanced binding and 
response to HulFN-~D, an IFN-~ subtype that is nota- 
bly weak in its effects on human cells, but which has 
strong interactions with bovine cells [26]. 
To investigate the intrinsic ligand binding properties 
of the human and bovine IFN-~R1 proteins in a cellular 
background devoid of other receptor subunits, we have 
expressed these proteins in Xenopus laevis oocytes. Xen- 
opus laevis is evolutionarily distant from mammals, and 
there are no reports of IFN-like antiviral activity in am- 
phibians or reptiles [27]. It is therefore reasonable to 
consider Xenopus as a 'null cell' with regard to the intro- 
duction of mammalian IFN receptor components. The 
ability of Xenopus oocytes microinjected with cRNA 
encoding human or bovine IFN-~R1 to bind human 
IFN-~A and -~B has been examined, and the resulting 
IFN-~/IFN-0~R1 complexes have been characterized by 
covalent crosslinking. These observations suggest hat 
the IFN-~RI subunit of the Type I IFN receptor plays 
a direct role in ligand binding. 
2. Mater ia ls  and methods 
Genetically engineered phosphorylatable IFN-~A and -~B were 
phosphorylated with the catalytic subunit of bovine heart cAMP-de- 
pendent protein kinase and [~'- 32p]ATP, as described [28,29]. Human 
Burkitt lymphoma-derived Daudi cells [30] and bovine kidney-derived 
MDBK cells [31] were used for binding and crosslinking controls. 
A full-length bovine IFN-~R1 cDNA was previously cloned and 
characterized [23]. HulFN-c~R 1 cDNA in the vector pYH 12 was the gift 
of Drs. Y. Hibino and S. Pestka. The coding regions of the receptor 
cDNAs were cloned into the transcription vector pSP64T [32] by blunt- 
end ligation [33], and the orientation of the inserts was confirmed. 
These clones were designated as BoIFN~R/pSP64T and HulFN~R/ 
pSP64T. Capped in vitro transcripts corresponding to the BolFN-~R1 
and HulFN-c~RI cRNAs were made from BolFN~R/ pSP64T and 
HulFN~R/pSP64T linearized with Sail and XbaI, respectively. The 
integrity and size of the transcripts were analyzed on 1% denaturing 
agarose gels [33]. 
Stage V-VI Xenopus laevis oocytes were prepared as described 
[34,35], with the addition of 1% horse serum to the Barth's solution. 
After 12-24 h, cRNA (50 nl at 1/~g//ll) from HulFN-~R1 or BolFN- 
~R 1 cDNA was injected into the cytoplasm of healthy oocytes. Control 
oocytes were injected with 50 nl of water. Injected oocytes were main- 
tained in the above medium at room temperature with daily changes 
of medium until tested for IFN binding activity. 
Injected oocytes were tested for IFN-~ binding after incubation for 
about 68 h. Microinjected oocytes were placed in 100/~1 of binding 
solution containing 1% non- fat dry milk (NFDM) and 2 x 105 cpm (ca. 
2 x 10 -t° M) of [32P]IFN-c~A or -~B in a 5 ml round bottom polypro- 
pylene tube (Falcon). Where appropriate, 3/~g of unlabeled HulFN-ccA 
was used as a competitor. Oocytes were incubated at room temperature 
for 1 h with rotation at 120 rpm, then washed 3 times with 0.5 ml of 
ice-cold binding solution and 3 times with I ml of ice- cold PBS. Oocytes 
were transferred to scintillation vials with scintillation fluid, vortexed 
for 1 rain, and radioactivity was quantitated. 
For measuring IFN binding to individual oocytes, the oocytes were 
transferred into a filter unit with a nylon membrane filter, and residual 
liquid was removed by gentle vacuum. A section of the membrane 
containing the oocyte was cut out and added to a scintillation vial 
containing 2 ml of scintillation fluid. The background level of radioac- 
tivity was determined for each vial prior to adding the washed oocytes. 
Covalent crosslinking of [32P]HulFN-~s to 50 oocytes/ batch was 
performed as described previously for mammalian cells [36,37]. Follow- 
ing binding of [32p]HulFN-~s and reaction with 0.5 mM disuccinimidyl 
suberate (DSS; Pierce Chemical Co.), oocytes were washed with 50 ml 
ice-cold PBS, allowed to settle, and liquid was removed by aspiration. 
Receptor-ligand complexes were extracted with 0.2 ml of 1% Triton 
X-100 with protease inhibitors. Insoluble material was then removed 
by centrifugation at 13,000 × g for 20 min at 4°C. Triton X-100 ex- 
tracts were analyzed by SDS-UREA-PAGE containing 7.5% acryl- 
amide and 6.7 M urea [38,39]. Gels were dried and subjected to auto- 
radiography. 
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Fig. 1. Binding of [32p]IFN-~A and -~B to Xenopus oocytes microin- 
jected with in vitro-made transcripts of HulFN-aR1 (A) and BolFN- 
~R1 (B). 5 oocytes in 100pl binding buffer were incubated with 2 x 105 
cpm of [32p]IFN-~A or -0~B, in the presence or absence of 3/tg non- 
radioactive IFN-~A, with gentle rotating for 1 h at room temp. The 
oocytes were washed and bound IFN was measured as described in 
section 2. Filled bars, binding in the absence of competitor ('Total 
binding'); open bars, binding in the presence of non-radioactive IFN- 
~A ('Non-specific binding'). 
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Fig. 2. Covalent crosslinking of [32PllFN-0IA to receptors on oocytes 
and bovine MDBK cells. Control water-injected oocytes (lanes 1,2), 
oocytes injected with the BolFN-0~RI transcript (lanes 3,4), and 
MDBK cells (lanes 5,6) were incubated with [32p]IFN-=A inthe absence 
(lanes 2,4,6) and presence (lanes 1,3,5) of 3 gg IFN-~A. The bound 
[32p]IFN-~A was crosslinked to the receptors and analyzed by SDS- 
PAGE and autoradiography as described in section 2. Positions of 
~4C-labeled molecular weight markers expressed in kDa are shown on 
the left. The 40 kDa band in lane 6 is a covalent dimer of IFN-0~A. 
3. Results and discussion 
Xenopus laevis oocytes were chosen as an expression 
system since they are highly unlikely to have IFN  recep- 
tors capable o f  interacting with mammal ian  IFN  recep- 
Table 1 
Ligand binding properties of IFN-~RI in different cell contexts 
Expressed Host Human IFNs Ref. 
eDNA cells 
IFN-~A IFN-~B IFN-ctD IFN-fl 
HulFN-ctR1 Murine - + nd - [14] 
CHO nd - nd + [41] 
COS 
(monkey) - - nd nd [23]* 
Xenopus + + nd nd 
BolFN-0tR1 Murine ++ ++ + nd [40]* 
COS ++ ++ nd nd [23] 
Human nd nd + nd [26] 
Xenopus ++ ++ nd nd 
nd, not done or not reported. 
*J.K.L. and J.A.L., unpublished ata. 
tor polypeptides,  and, indeed, may not have an IFN  
system at all [27]. Consistent with this assumption,  
water- injected oocytes bound human IFN-~A and -~B 
poor ly  (Figs. 1 and 3), and produced no evidence of  any 
I FN- receptor  complexes in covalent crossl inking experi- 
ments (Figs. 2 and 4). 
3.1. Ligand binding properties o f  the bovine IFN-o~R1 
polypeptide 
Oocytes were microinjected with RNA transcripts 
made in vitro from the eDNA for the bovine IFN-~R1.  
Two-to-three days after injection, binding of  both 
[32p]HulFN-0~A and -~B, corresponding,  respectively, to 
1.3 × 109 and 3.0 x 109 IFN  molecules per oocyte, was 
measured for oocytes injected with the Bo lFN-~R1 
RNA transcript (Fig. 1B). Most  binding was blocked by 
the addit ion of  excess IFN-0~A, demonstrat ing that the 
binding is specific. Control  water- injected oocytes dis- 
played low levels of  non-specific binding, and no specific 
binding of  either l igand. 
In affinity crossl inking experiments (Fig. 2), oocytes 
expressing the BolFN-0~R1 polypept ide displayed a 
broad band centered at 155 kDa,  corresponding to the 
[32P]HulFN-ctA/receptor complex, and several weaker 
bands, including one of  >220 kDa,  and several between 
130 and 95 kDa.  The nature of  these minor  bands is 
unknown,  but may reflect heterogeneous processing of  
the BolFN-0tR1 polypept ide in Xenopus. Addi t ion  o f  
excess non-radioact ive IFN-~A abol ished these bands 
(lanes 3 and 5). This pattern can be compared to the 
broad 140 kDa complex, sometimes discernable as a 
doublet,  formed on control  bovine MDBK cells (Fig. 2, 
lane 6). The difference in electrophoretic mobi l i ty  of  the 
receptor - l igand complex from injected Xenopus oocytes 
with that on MDBK cells may represent differences in 
glycosylat ion or processing. Alternatively, the difference 
Table 2 
Binding of [32p]HulFN-0~A to bovine MDBK cells and murine cells 
transfected with the BolFN-~RI eDNA 
Cell type K a (M ~) Receptors/cell 
MDBK 6.8 x 10-" 1500 
BolFNAR/3T3 8.6 x 10 -11 2470 
BolFNAR/L 10.7 × 10 -tI 1325 
For expression of the BolFN-0~R1 in rodent cells, the BolFN-~R1 
eDNA was subcloned into expression vector pD5/IgH-En/Hygro B 
[44]. Plasmids derived from pD5/IgH-En/Hygro B were transfected into 
mouse NIH/3T3 or L cells by the polybrene-DMSO procedure [45], and 
transformants were selected with 250 gg/ml hygromycin B. After 10 
days of selection, well-isolated healthy colonies were transferred to 
24-well plates. These subclones were screened for binding of HulFN-c~s. 
The selected clones derived from NIH3T3 cells and L cells were desig- 
nated BolFNAR1/3T3 and BolFNAR1/L, respectively. The binding of 
[32p]HulFN-0~A tobovine MDBK and BolFNAR1/3T3 cells was meas- 
ured by incubating cells with various amounts of 32p-labeled ligand 
(I.4 × 10-" M 1 x 10 -9 M) for 1 h at room temperature, and samples 
were processed as described [23,36,37]. Untransfected NIH-3T3 cells do 
not show high affinity specific binding of [32p]HulFN-~A. 
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Fig. 3. Binding of [32p]IFN-~A and -c~B to individual Xenopus oocytes microinjected with in vitro-transcribed HulFN-~R1 RNA. Individual oocytes 
were injected with 50 ng of HulFN-~R1 transcript and assayed 3 days later (see section 2). The value for each oocyte is plotted as a separate symbol. 
(A) Binding of [32p]HulFN-c~A. (B) Binding of [32p]HulFN-ctB. The values above the symbol ' - '  represent total binding, in the absence of excess 
non-radioactive IFN-c~A; values above the symbol '+' represent on-specific binding, measured in the presence of excess HulFN-~A, 
may result from cross-linking to other components ofthe 
IFN-~ receptor in MDBK cells. Nevertheless, identifica- 
tion of the 155 kDa receptor/ligand complex in oocytes 
injected with the BoIFN-~R1 transcript constitutes di- 
rect evidence that the BolFN-~R1 subunit is sufficient 
for IFN-~ binding. 
The results of the current experiments with Xenopus 
oocytes are consistent with our previous observation that 
COS cells transiently transfected with the BoIFN-~R1 in 
pcDNA1 have 0.25-1 × 106 high-affinity binding sites for 
HuIFN-~A and <zB, compared to <104 receptors for 
HuIFN-~A and -~B on untransfected COS cells ([23]; 
Table 1). The high-affinity binding of HuIFN-~s to the 
BolFN-~R1 polypeptide may account for the fact that 
mouse or human cells stably transfected with the BolFN- 
~R1 protein acquire the ligand binding affinities and 
specificities for human IFN-~s characteristic of bovine 
cells (e.g. Table 2, and unpublished data; [26,40]). 
3.2. Ligand binding properties of the human IFN-o~R1 
polypeptide 
Previous tudies of the human IFN-~R1 polypeptide 
expressed in various heterologous host cells have not 
produced firm conclusions on its role in IFN binding, 
and the ligand specificity appears to be strongly modu- 
lated by factors in the host cell ([14,23,41]; Table 1). 
In the present study, Xenopus oocytes microinjected 
with the HuIFN-~R1 transcript exhibited significant 
specific binding of both [32p]IFN-~A and -czB (Fig. 1A), 
corresponding to 2.6 × 10 7 and 9.6 × 10 7 IFN molecules 
bound per oocyte. Binding to individual oocytes was also 
measured (Fig. 3). At the subsaturating concentration f 
IFN-~s used, the average specific binding per oocyte, 
estimated from measurements on 10 individual oocytes, 
was ca. 5.5× 107 molecules of [32P]HulFN-~A and 
1.7 × 108 molecules of [32p]HulFN-~B. The differences in
binding in the presence and absence of excess unlabeled 
IFN-~ were highly significant (t-values of 18.36 for 
[32p]HulFN-~A and 20.58 for [32p]HulFN-0~B). 
The specific binding of [32p]HulFN-c~B to the ex- 
pressed HulFN-~R1 was confirmed by crosslinking ex- 
periments. A single 140 kDa band representing the recep- 
Top - -  
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180- -  
116 - -  
84 - -  
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Fig. 4. Covalent cross-linking of [~2P]IFN-c~B to the receptors on 
human Daudi cells and oocytes injected with the HulFN-ctR1 cRNA. 
Daudi cells or oocytes were incubated with [32p]IFN-c~B and processed 
as described in Fig. 2. Odd lanes represent reaction containing excess 
non-radioactive IFN-ccA and even lanes represent without. (Because 
much less Daudi sample was loaded, the Daudi controls in lanes 1 and 
2 were density- and contrast-enhanced by computer to better visualize 
the bands. The lanes from oocyte samples were not manipulated.) 
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tor-l igand complex was observed (Fig. 4, lanes 3 and 4). 
This complex displayed a slightly slower electrophoretic 
mobility than the upper band observed with Daudi cells 
(ca. 130-135 kDa) (Fig. 4, lane 2); it is possible that the 
IFN-~R1 subunit expressed on Xenopus oocytes is more 
heavily glycosylated or represents a different subunit 
from the major band seen with Daudi cells. It is signifi- 
cant that a single crosslinked band is seen with the 
oocytes, whereas the analogous experiment on human 
cells produces several bands (Fig. 4, lane 2; [19,42]). 
Some of these bands have been identified as complexes 
of I FN-a  with other human cell surface proteins, pre- 
sumably other subunits of the receptor [18,19,21]. These 
observations are also consistent with the possibility that 
the Hu IFN-~RI  polypeptide xpressed in oocytes is but 
one subunit of the putative multi-subunit Type I I FN 
receptor. 
The low levels of IFN binding to oocytes expressing 
the HuIFN-0~R1 preclude Scatchard analysis and deter- 
mination of dissociation constants. Since high expression 
of the bovine homologue was observed in this system, it 
is likely that the low levels of IFN binding reflect a low 
affinity for HuIFN-~s, rather than a failure to express 
protein efficiently. This likelihood is speculative, since 
we currently lack an independent method for quanti- 
tating cell surface HuIFN-~R1 expression (e.g. appro- 
priate antibodies). The high sensitivity of detection of 
IFN binding in the oocyte system may reflect the ex- 
tremely low background for IFN binding on oocytes; in 
our previous experiments with COS cells ([23]; unpub- 
lished data), the high background arising from en- 
dogenous COS high affinity IFN-~ receptors may have 
obscured low affinity binding by the Hu IFN-~RI  poi- 
ypeptide, despite strong expression of the protein. 
We have demonstrated directly that the human and 
bovine IFN-0~R1 polypeptides have the intrinsic ability 
to bind IFN-~A and IFN-aB; previously, such a role 
could only be inferred indirectly from immunochemical 
evidence [15,16]. The recently identified HuIFN-~R2 
also seems to have a broad ability to bind Type I IFNs, 
probably with much higher affinity than the HuIFN-  
aR l ,  although the affinity has not yet been measured 
[17]. That these are both subunits of a common receptor 
is indicated by the ability of antibodies to either protein 
to neutralize the binding and activity of a variety of Type 
I IFNs to human cells [15-17]. The co-expression of these 
two polypeptides i of great interest, and it is not yet 
known whether these are the only subunits of the Type 
I receptor (e.g. [22]). There is also evidence suggesting a 
role for the HuIFN-c~R1 in signal transduction [24,25]. 
Thus, the IFN-czR 1 polypeptide may play roles in both 
ligand binding and signal transduction, and the simple 
schema [43] whereby cytokine ligand binding is assigned 
to an '0~ subunit' and signal transduction is assigned to 
a 'fl subunit' may not reflect the complexity of the Type 
I I FN receptor. 
Finally, the contrasting abilities of the human and 
bovine IFN-c~R1 proteins to bind human IFN-c~s pro- 
vides a powerful system for mapping IFN binding deter- 
minants of these proteins, 
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